Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri
A
A
Barbui
T
T
Boccadoro
M
M
Comotti
B
B
Dammacco
F
F
Gallamini
A
A
Marmont
F
F
Neretto
G
G
Petrucci
M T
MT
Resegotti
L
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002330:Carmustine / Q000008:administration & dosage; D002453:Cell Cycle; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D010265:Paraproteinemias / Q000175:diagnosis; D010950:Plasma Cells / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone